TD Cowen Keeps Buy Rating on Senseonics Holdings, Reduces Price Target to $15

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Nov 05 2025

0mins

SENS+7.53%

Should l Buy SENS?

Source: Benzinga

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SENS?" and start using high-conviction signals backed by rigorous historical data.

SENS

$7.43+Infinity%1D

Analyst Views on SENS

Wall Street analysts forecast SENS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SENS is 18.70 USD with a low forecast of 9.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 6.910

Low

9.00

Averages

18.70

High

31.00

Current: 6.910

Low

9.00

Averages

18.70

High

31.00

Mizuho

Outperform

NULL

downgrade

$40 -> $20

2025-11-10

Reason

Mizuho

Price Target

$40 -> $20

AI Analysis

2025-11-10

downgrade

Outperform

NULL

Reason

Mizuho lowered the firm's price target on Senseonics to $20 from $40 and keeps an Outperform rating on the shares post the Q3 report. The firm believes the company's setup remains favorable into Q4 amid tailwinds from the start of E365 new starts, renewals and expanding inserter network.

H.C. Wainwright

Buy

maintain

2025-11-06

Reason

H.C. Wainwright

Price Target

2025-11-06

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Senseonics to $18.50 from $1.40 and keeps a Buy rating on the shares. The firm cites the 1-for-20 reverse stock split for the target change.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SENS

Unlock Now

About SENS

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue

Jan 20 2026Yahoo Finance

Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.

Senseonics (SENS) Reports Q4 2025 Revenue of ~$14.2M with 103% New Patient Growth

Jan 12 2026seekingalpha

Significant Revenue Growth: Senseonics reported preliminary unaudited Q4 2025 revenue of approximately $14.2 million and annual revenue of about $35.2 million, indicating strong market performance, with expectations for 2026 global net revenue to reach $58-$62 million, reflecting a growth of 65% to 76%.
Innovative Patient Growth: The company achieved a remarkable 103% new patient growth in the U.S. during Q4, marking the largest addition of new patients in its history, primarily driven by effective direct-to-consumer marketing strategies, showcasing the effectiveness of its promotional efforts and enhanced brand influence.
Gross Margin Expectations: Senseonics anticipates a gross margin of approximately 50% for 2026, which will further enhance its profitability and provide funding support for future investments and expansions, reflecting success in cost control and product pricing strategies.
Enhanced Financial Transparency: The company plans to release its Q4 and full-year 2025 financial results on March 2, 2026, which will provide more financial details and bolster investor confidence in the company's future development, while also expecting a cash and cash equivalents balance of about $94.3 million as of December 31, 2025.

sensiBel Launches SBM100B Microphone, Delivers Studio-Quality Audio in Compact Form

Dec 10 2025Globenewswire

Audio Breakthrough: The SBM100B microphone from sensiBel achieves an 80dB signal-to-noise ratio and an acoustic overload point of up to 146dB, delivering studio-quality audio suitable for conferencing and industrial sound detection, significantly enhancing recording flexibility and clarity.
Technological Innovation: Leveraging optical MEMS core technology, the SBM100B overcomes traditional MEMS microphone limitations by using laser interferometry to detect membrane movement, enabling a wider dynamic range and lower noise floor while maintaining a compact form factor, thus advancing audio technology.
Convenient Solutions: The AURORA and POLARIS kits connect via USB-C, allowing users to start recording within minutes without soldering or specialized tools, greatly simplifying the design process and enhancing product competitiveness in the market.
Diverse Applications: The SBM100B is applicable in various scenarios such as video conferencing and spatial audio capture, providing exceptional directionality and high bandwidth to meet the growing market demand, supporting sensiBel's transformation and growth in the audio industry.

Examining Senseonics' Story Following Analyst Adjustments and Product Pipeline Developments

Dec 07 2025Yahoo Finance

Analyst Adjustments: Senseonics Holdings maintains a fair value of approximately $18.92 per share, with slight adjustments in discount rates and revenue growth expectations reflecting a recalibration rather than a fundamental change in the company's long-term outlook.
Bullish and Bearish Perspectives: TD Cowen remains bullish with a Buy rating despite lowering its price target to $15, while Stifel adopts a more cautious Hold rating with a $9 target, highlighting execution and capital risks as key concerns.
Market Visibility and Listing Changes: Senseonics has been added to the NASDAQ Composite Index and will transfer its primary listing to the Nasdaq Global Select Market in 2025, enhancing its visibility among institutional investors.
Future Growth Projections: The company targets $35 million in global net revenue for 2025, driven by the U.S. rollout of Eversense 365 and a doubling of its patient base, while also executing a reverse stock split to maintain listing compliance.

Senseonics Shares Decline as 2025 Forecast Falls Short of Expectations

Nov 06 2025SeekingAlpha

Financial Performance: Senseonics Holdings reported Q3 2025 revenue of $8.1M, reflecting nearly 90% year-over-year growth, but set its full-year revenue outlook at $35M, below analyst expectations of $36.3M.
Net Loss and Margins: The company's net loss narrowed by 19% year-over-year to $19.5M, missing consensus estimates, despite cuts to R&D expenses and improved gross margins for its Eversense 365 glucose monitoring devices.